MHC-HM424T-100μg / 询价
MHC-HM424T-500μg / 询价
MHC-HM424T-500μgx2 / 询价
- 客服电话
- 技术支持
Chimeric HLA-A*02:01 (mα3) &B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein
Recombinant Chimeric HLA-A*02:01(mα3)&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr206(Human HLA-A*02:01 α1&α2)&Asp140-Lys241(Mouse H-2Ld α3), Ile21-Met119 (B2M) and SLLMWITQC [Accession | A0A140T913(Human HLA-A*02:01 α1&α2)&P01895(Mouse H-2Ld α3)&P61769(B2M)&SLLMWITQC].
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Chimeric HLA-A*02:01 (mα3) &B2M&NY-ESO-1 (SLLMWITQC) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Chimeric HLA-A*02:01 (mα3) &B2M&NY-ESO-1 (SLLMWITQC) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Chimeric HLA-A*02:01 (mα3) &B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag with the EC50 of 17.3ng/ml determined by ELISA.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
